Brokerages Set Humacyte, Inc. (NASDAQ:HUMA) Price Target at $11.71

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) has earned an average rating of "Buy" from the eight research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $11.71.

Several equities analysts recently weighed in on the company. Benchmark lowered their target price on Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Wall Street Zen upgraded Humacyte from a "sell" rating to a "hold" rating in a research report on Friday, June 27th. D. Boral Capital restated a "buy" rating and issued a $25.00 price objective on shares of Humacyte in a research report on Monday, June 9th. Finally, HC Wainwright initiated coverage on Humacyte in a research report on Wednesday, May 14th. They issued a "buy" rating and a $4.00 price objective on the stock.

Insider Activity

In other news, CFO Dale A. Sander bought 20,000 shares of Humacyte stock in a transaction dated Thursday, April 10th. The shares were purchased at an average cost of $1.53 per share, with a total value of $30,600.00. Following the completion of the acquisition, the chief financial officer owned 40,600 shares of the company's stock, valued at $62,118. This trade represents a 97.09% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders bought 33,993 shares of company stock valued at $52,224 over the last quarter. Insiders own 5.10% of the company's stock.

Institutional Investors Weigh In On Humacyte

Several large investors have recently made changes to their positions in HUMA. Columbia Advisory Partners LLC bought a new stake in shares of Humacyte in the first quarter worth about $27,000. Hamilton Lane Advisors LLC bought a new stake in shares of Humacyte in the first quarter worth about $37,000. Letko Brosseau & Associates Inc. bought a new stake in Humacyte during the first quarter worth approximately $42,000. Petros Family Wealth LLC bought a new stake in Humacyte during the fourth quarter worth approximately $50,000. Finally, Syon Capital LLC bought a new stake in Humacyte during the fourth quarter worth approximately $54,000. 44.71% of the stock is owned by institutional investors.

Humacyte Stock Performance

NASDAQ HUMA traded up $0.41 on Monday, hitting $2.57. 14,385,497 shares of the company traded hands, compared to its average volume of 3,825,758. The company has a market capitalization of $398.66 million, a price-to-earnings ratio of -3.72 and a beta of 1.89. The company has a current ratio of 3.68, a quick ratio of 3.28 and a debt-to-equity ratio of 0.36. The business's 50 day moving average price is $2.15 and its 200-day moving average price is $2.92. Humacyte has a 52-week low of $1.15 and a 52-week high of $9.79.

Humacyte (NASDAQ:HUMA - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.09. The company had revenue of $0.52 million for the quarter, compared to analysts' expectations of $0.46 million. Equities analysts expect that Humacyte will post -1.27 earnings per share for the current year.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.